{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:45Z","timestamp":1786991625471,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["NIHR202952"],"award-info":[{"award-number":["NIHR202952"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK 089507"],"award-info":[{"award-number":["P30 DK 089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.01.011","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T15:13:51Z","timestamp":1707578031000},"page":"746-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries"],"prefix":"10.1016","volume":"23","author":[{"given":"Rebecca","family":"Calthorpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Derleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobh\u00e1n B","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.01.011_bib0001","unstructured":"CFT. Cystic Fibrosis Trust: UK Cystic Fibrosis Registry 2021 Annual Data Report. 2022 4 April 2023]; Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-10\/CFT_2021-Annual-Data-Report-WEB.pdf."},{"key":"10.1016\/j.jcf.2024.01.011_bib0002","unstructured":"CFF. Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report. 2022 4 April 2023]; Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"10.1016\/j.jcf.2024.01.011_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.011_bib0004","unstructured":"CFT. Cystic Fibrosis Trust: cystic Fibrosis FAQs. 2022 4 April 2023]; Available from: https:\/\/www.cysticfibrosis.org.uk\/what-is-cystic-fibrosis\/faqs#What%20is%20cystic%20fibrosis?"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.011_bib0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.011_bib0006","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jcf.2024.01.011_bib0007","unstructured":"JLA. James Lind Alliance Priority Setting Partnerships: cystic Fibrosis Refresh Top 10 Priorities (priority setting in association with the JLA). 2022 4 April 2023]; Available from: https:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/cystic-fibrosis-refresh\/top-10-priorities.htm."},{"issue":"12","key":"10.1016\/j.jcf.2024.01.011_bib0008","article-title":"Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis","volume":"12","author":"Carroll","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.011_bib0009","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102235","article-title":"Animal models of cystic fibrosis in the era of highly effective modulator therapies","volume":"64","author":"Grubb","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"10.1016\/j.jcf.2024.01.011_bib0011","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.01.011_bib0012","first-page":"99","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2024.01.011_bib0013","first-page":"182","volume":"18","author":"Hutchinson","year":"2021"},{"issue":"10","key":"10.1016\/j.jcf.2024.01.011_bib0014","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/ppul.24952","article-title":"Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor","volume":"55","author":"Smith","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.jcf.2024.01.011_bib0015","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/ppul.25047","article-title":"Reversing the irreversible: another potential benefit of CFTR modulators","volume":"55","author":"Wright","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.jcf.2024.01.011_bib0016","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ppul.24454","article-title":"Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor","volume":"54","author":"Hamilton","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2024.01.011_bib0017","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.011_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.011_bib0019","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.011_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ije\/dyx196","article-title":"Data Resource Profile: the UK Cystic Fibrosis Registry","volume":"47","author":"Taylor-Robinson","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcf.2024.01.011_bib0021","first-page":"1173","volume":"13","author":"Knapp","year":"2016"},{"key":"10.1016\/j.jcf.2024.01.011_bib0022","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.011_bib0023","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcf.2024.01.011_bib0024","doi-asserted-by":"crossref","unstructured":"Emery, J., D. Mullane, and M.N. Chroinin, GP284\u2005The effects of ivacaftor on pancreatic function in paediatric patients with cystic fibrosis gating mutations. 2019: p. A149.2\u2013A150.","DOI":"10.1136\/archdischild-2019-epa.343"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.011_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.01.011_bib0026","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1542\/peds.2014-3698","article-title":"Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening","volume":"135","author":"Ren","year":"2015","journal-title":"Pediatrics"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:09:29Z","timestamp":1783019369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000122"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}